Closed · W81XWH-16-NFRP-CTA · CFDA 12.420 · Discretionary

DoD Neurofibromatosis Clinical Trial Award

Federal grant opportunity posted by Defense Health Agency Contracting Activity - DHACA, cataloged on Grants.gov.

Varies
Award range
Closed
Status
August 1, 2016
Close date
1
Expected awards

The verdict

DoD Neurofibromatosis Clinical Trial Award is a closed discretionary listing from Defense Health Agency Contracting Activity - DHACA that offered Varies by applicant across 1 expected award. Future funding cycles may be published under the same CFDA number. PlainGrants indexes 1,795 other opportunities from Defense Health Agency Contracting Activity - DHACA.

Varies
award range
Closed
application status
1
expected award
12.420
CFDA program

Archived opportunity record

DoD Neurofibromatosis Clinical Trial Award is closed (last close August 1, 2016). Check the agency catalog for replacement NOFOs. Defense Health Agency Contracting Activity - DHACA still indexes 1,795 other opportunities here.

According to Grants.gov (extract vintage 2026-08-10), this record reflects the officially published listing. See methodology.

Deadline tracker

Application window closed

Closed August 1, 2016

Posted May 9 Closes Aug 1

Est. Total Funding

$1,440,000

Expected Awards

1

Instrument

Grant

Description

The NFRP Clinical Trial Award supports research with the potential to have a major impact on the treatment or management of NF. Clinical trials may be designed to evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance, and/or emerging approaches and technologies. Proposed projects may range from small proof-of-concept (i.e., pilot, first in human, or Phase 0) trials to demonstrate feasibility or inform the design of more advanced trials, through large-scale trials to determine efficacy in relevant patient populations. Funding from this award mechanism must support a clinical trial and may not be used for preclinical research studies. A clinical trial is defined as a prospective accrual of human subjects where an intervention (e.g., device, drug, biologic, surgical procedure, rehabilitative modality, behavioral intervention, or other) is tested on a human subject for a measurable outcome with respect to exploratory information, safety, effectiveness, and/or efficacy. This outcome represents a direct effect on the human subject of that intervention or interaction. Principal Investigators (PIs) seeking funding for a preclinical research project should consider one of the other award mechanisms/Funding Opportunities being offered by the FY16 NFRP. The term “human subjects” is used in this Program Announcement/Funding Opportunity to refer to individuals who will be recruited for or who will participate in the proposed clinical trial. For more information, a Human Subject Resource Document is provided at https://ebrap.org/eBRAP/public/Program.htm. If the clinical trial involves the use of a drug that has not been approved by the U.S. Food and Drug Administration (FDA) for the proposed investigational use, then evidence that an Investigational New Drug (IND) application that meets all requirements under the Code of Federal Regulations, Title 21, Part 312 (21 CFR 312) has been submitted to the FDA prior to the application submission deadline, or that the drug is exempt from an IND, is required. If the investigational product is a device, evidence that an Investigational Device Exemption (IDE) application that meets all requirements under 21 CFR 812 has been submitted to the FDA prior to the application submission deadline, or that the device is exempt from an IDE, is required. The NFRP IND/IDE Documentation Form (Attachment 13) should be included in the application. Documentation of approval of the IND or IDE must be obtained and submitted to the CDMRP Help Desk (help@eBRAP.org) prior to Programmatic Review; otherwise, the Government reserves the right to withdraw the application. The following are important aspects of submission for the Clinical Trial Award: • The proposed clinical trial is expected to begin no later than 6 months after the award date. The 6 months includes the time required for regulatory review and approval processes. • The application should include a clearly articulated statistical analysis plan appropriate to the phase of the clinical trial, a power analysis reflecting sample size projections that will clearly answer the objectives of the study, and appropriate statistical expertise. • The application must demonstrate documented availability and accessibility of the drug/compound, device, and/or other materials needed, e.g., a letter from the manufacturer assuring an adequate supply of the agent (and placebo, if necessary). • The application must demonstrate documented availability of, and access to, a suitable patient population that will support a meaningful outcome for the study. The PI should discuss how accrual goals will be achieved and maintained and how standards of care may impact the study population. • The application must include, as appropriate, a study coordinator(s) who will guide the clinical protocol through the local Institutional Review Board (IRB) of record and other regulatory approval processes, coordinate activities from all sites participating in the clinical trial, and coordinate participant accrual. • The application should include a transition plan (including potential funding and resources) showing how the product will progress to the next clinical trial phase and/or delivery to the market after the successful completion of the NFRP Clinical Trial Award. • The application should clearly demonstrate strong institutional support and commitment. • The proposed clinical trial design should include clearly defined and appropriate endpoints, and follow Good Clinical Practice (GCP) guidelines. • The application should include a clearly articulated clinical monitoring plan, outlining how the study will be monitored for GCP compliance. • The application should include a clearly articulated data management plan and use of an appropriate database to safeguard and maintain the integrity of the data. • The application should include a clearly articulated safety management plan, outlining how safety pharmacovigilance will be conducted as applicable. • The application should acknowledge commitment to filing the study in the NIH clinical trials registry, www.clinicaltrials.gov. Multi-Institutional Clinical Trials: If the proposed clinical trial is multi-institutional, plans for communication and data transfer among the collaborating institutions, as well as how specimens and/or imaging products obtained during the study will be handled, should be included in the appropriate sections of the application. A separate intellectual and material property plan agreed upon by all participating institutions is also required for multi-institutional clinical trials. Refer to Attachments 8 and 9 for additional information.

Catch-all / unrestricted eligibility mark · W81XWH-16-NFRP-CTA

Grants.gov marks DoD Neurofibromatosis Clinical Trial Award with a catch-all / unrestricted eligibility code (Unrestricted / see official listing). Read the official announcement text for the real applicant filter — the code alone is not a door list. The extract does not mark applicant cost-sharing as required. Instrument: Grant. Funding-activity code maps to Science and Technology / R&D (ST). This eligibility-code string dominates the Defense Health Agency Contracting Activity - DHACA book (1,791 peers, 100% of 1,796).

Code 99
Unrestricted / see official listing

Codes are Grants.gov eligibility category values from the extract vintage 2026-08-10. Confirm the full eligibility statement on the official listing or the Grants.gov eligibility reference.

Official Listing on Grants.gov

View full details, application forms, and submission instructions.

View on Grants.gov

Agency Contact

CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org

What to do next

DoD Neurofibromatosis Clinical Trial Award is closed; use the parent program and agency catalog for the next funding cycle.

  • Browse open federal opportunities in the same category when this listing is closed. Open opportunities
  • Look up CFDA 12.420 across all indexed listings before you commit to this opportunity alone. Eligibility finder
  • Compare award ranges across federal categories before you pick a single CFDA. All categories

Opportunity deadlines and eligibility change on Grants.gov; PlainGrants mirrors the extract and is not the submission system.

Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.

Data sourced from the SAM.gov Assistance Listings and Grants.gov. See our methodology for details. Retrieved and formatted by PlainGrants